Serum Anti-Mullerian Hormone Levels Might Indicate Premenopausal Endometrial Lesions

被引:0
|
作者
Yao, Yingsha [1 ]
Shi, Liujing [1 ]
Zhu, Xiaoming [1 ,2 ]
机构
[1] Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou 310006, Peoples R China
[2] Zhejiang Univ, Womens Hosp, Sch Med, Key Lab Womens Reprod Hlth Zhejiang Prov, Hangzhou 310006, Peoples R China
关键词
polycystic ovary syndrome; endometrial proliferative lesions; anti-Mullerian hormone; threshold value; regression model; POLYCYSTIC-OVARY-SYNDROME; CANCER STATISTICS; RISK; HYPERPLASIA; ULTRASOUND; PREDICTION; CONSENSUS; CRITERIA; CA125; HE-4;
D O I
10.3390/diagnostics13213301
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Endometrial proliferative lesions (EPL) usually refer to endometrial hyperplasia (EH) and endometrial cancer (EC). Among patients with premenopausal EPL who wish to preserve their fertility, only those with EH and early-stage EC have the possibility to undergo fertility preservation therapy. However, there is currently a lack of specific and reliable screening criteria and models for identifying these patients. Methods: This study utilized a retrospective diagnostic study design. The training set included medical record information that met the criteria between August 2017 and October 2022, while the validation set consisted of medical record information that met the criteria from November 2022 to May 2023. The endometrial pathological test served as the gold standard. The serum anti-Mullerian hormone (AMH) level before endometrial sampling and a regression model were employed to predict EPL. Results: The study included a total of 1209 patients with PCOS (1119 in the control group and 90 in the endometrial proliferative lesion group) and 5366 women without PCOS (5249 in the control group and 117 in the proliferative lesion group). In the case of PCOS patients aged 20-39 years, the most effective screening threshold for AMH was found to be a serum AMH level of <= 5.39 ng/mL. The model used for this group was logit(p) = -2.562 - 0.430 x AMH + 0.127 x BMI + 1.512 x hypertension + 0.956 x diabetes -1.145 x regular menstruation. On the other hand, for non-PCOS women aged 20-39 years, the optimal screening threshold for AMH was determined to be a serum AMH value of <= 2.18 ng/mL. The model used for this group was logit(p) = -3.778 - 0.823 x AMH + 0.176 x BMI + 2.660 x diabetes -1.527 x regular menstruation -1.117 x dysmenorrhea. It is important to note that all of these findings have successfully passed internal verification. Conclusion: For PCOS and non-PCOS women aged 20-39 years, the serum AMH test and related multiple regression models were obtained for the warning of EPL.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Serum anti-Mullerian hormone levels are associated with low bone mineral density in premenopausal women
    Yan, Yuzhu
    Chen, Wei
    Wang, Jihan
    Huang, Jing
    Lv, Jing
    Zhao, Heping
    Guo, Lei
    [J]. BIOMARKERS, 2020, 25 (08) : 693 - 700
  • [2] Application of machine learning tools for evaluating the impact of premenopausal hysterectomy on serum anti-mullerian hormone levels
    Sreenu, Boddupally
    Kameswari, S., V
    Naushad, Shaik Mohammad
    Kutala, Vijay Kumar
    [J]. INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS, 2020, 57 (02): : 245 - 251
  • [3] THE IMPACT OF SERUM ANTI-MULLERIAN HORMONE ON FOLLICULAR PHASE LENGTH IN PREMENOPAUSAL WOMEN
    Kissell, Kerri
    Danaher, Michelle
    Schisterman, Enrique
    Perkins, Neil
    Schliep, Karen
    Ahrens, Katherine
    Sjaarda, Lindsey
    Wactawski-Wende, Jean
    Mumford, Sunni
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2013, 177 : S149 - S149
  • [4] Assessment of anti-Mullerian hormone levels in premenopausal patients with systemic lupus erythematosus
    Gasparin, A. A.
    Souza, L.
    Siebert, M.
    Xavier, R. M.
    Chakr, R. M. S.
    Palominos, P. E.
    Brenol, J. C. T.
    Monticielo, O. A.
    [J]. LUPUS, 2016, 25 (03) : 227 - 232
  • [5] The association between anthropometric factors and anti-Mullerian hormone levels in premenopausal women
    Grimes, Nydjie P.
    Whitcomb, Brian W.
    Reeves, Katherine W.
    Sievert, Lynnette L.
    Purdue-Smithe, Alexandra
    Manson, JoAnn E.
    Hankinson, Susan E.
    Rosner, Bernard A.
    Bertone-Johnson, Elizabeth R.
    [J]. WOMEN & HEALTH, 2022, 62 (07) : 580 - 592
  • [6] Serum anti-mullerian hormone levels in women with secondary amenorrhea
    La Marca, Antonio
    Pati, Marianela
    Orvieto, Raoul
    Stabile, Gaspare
    Artenisio, Alfredo Carducci
    Volpe, Annibale
    [J]. FERTILITY AND STERILITY, 2006, 85 (05) : 1547 - 1549
  • [7] Serum anti-Mullerian hormone levels in women with secondary amenorrhea
    La Marca, A.
    Giulini, S.
    Pati, M.
    Levratti, P.
    Tirelli, A.
    Mehmeti, I.
    Volpe, A.
    [J]. HUMAN REPRODUCTION, 2006, 21 : I104 - I104
  • [8] Serum Anti-Mullerian Hormone Levels in Patients with Epithelial Ovarian Cancer
    Walentowicz, Pawel
    Sadlecki, Pawel
    Krintus, Magdalena
    Sypniewska, Grazyna
    Mankowska-Cyl, Aneta
    Grabiec, Marek
    Walentowicz-Sadlecka, Malgorzata
    [J]. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2013, 2013
  • [9] Serum anti-Mullerian hormone levels during estrus and diestrus in mares
    Dal, Gamze Evkuran
    Kasikci, Guven
    [J]. MEDYCYNA WETERYNARYJNA-VETERINARY MEDICINE-SCIENCE AND PRACTICE, 2020, 76 (05): : 282 - 284
  • [10] Undetectable serum anti-Mullerian hormone levels and occurrence of ongoing pregnancy
    Fraisse, Timothee
    Ibecheole, Victoria
    Streuli, Isabelle
    Bischof, Paul
    de Ziegler, Dominique
    [J]. FERTILITY AND STERILITY, 2008, 89 (03) : 723.e9 - 723.e11